Study to Assess AFM24 in Advanced Solid Cancers

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody being developed to target EGFR-expressing solid tumors and has been designed to specifically utilize the cytotoxic potential of the innate immune system, in particular natural killer cells and macrophages for the specific and efficient elimination of EGFR expressing cancer cells.

Key facts

Study ID: NCT04259450
Run by: Affimed GmbH
People needed: 85
Starts: 2020-04-07
Expected to finish: 2024-06-24
Last updated by the study team: 2025-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adequate organ function
Phase 1: Histologically or cytologically confirmed advanced or metastatic solid malignancies that are known to express EGFR
Phase 1: Previously treated with ≥ 1 lines of anticancer therapy and have documented disease progression during or after their most recent line of anticancer therapy. In addition, either there is no further SOC therapy for the patient or the remaining SOC therapies are deemed not appropriate for the patient by the Investigator.
Phase 1: Patients must have at least one tumor site that is accessible to biopsy
Phase 2a: Measurable disease per RECIST 1.1
Phase 2a: Histologically confirmed advanced or metastatic EGFR+ malignancies for each expansion cohorts:
Colorectal Cancer (MSS), KRAS-wildtype: disease has progressed after ≥ 2 prior lines of therapy which must have included oxaliplatin, fluoropyrimidine, bevacizumab, and an anti-EGFR therapy
ccRCC: disease has progressed after ≥ 2 prior lines of therapy which must have included a TKI and a checkpoint inhibitor
metastatic NSCLC, EGFRmut: disease has progressed on/after after ≥ 1 prior lines of therapy for advanced disease including ≥ 1 prior TKI approved for EGFR mut NSCLC

You may not qualify if…

Treatment with systemic anticancer therapy within 4 weeks of the first dose of study drug (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent if half-life is known and it is shorter, before first dose of study drug. Anticancer therapies include cytotoxic chemotherapy, targeted inhibitors, and immunotherapies, but do not include hormonal therapy or radiotherapy.
Radiation therapy within 2 weeks before 1st dose of study drug or unresolved toxicity from previous radiotherapy.
History of any other malignancy known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, DCIS, early stage prostate cancer that has been adequately treated, and other cancers from which the patient has been disease free for 3 years or longer.
Currently participating in a study and receiving study therapy, or participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.

Where it is running

University of Southern California — Los Angeles, California, United States
Dana Faber Cancer Institute — Boston, Massachusetts, United States
Nordwest Hospital GmbH — Frankfurt am Main, Hesse, Germany
University Duisburg-Essen, University Hospital Essen — Essen, Germany
University Hospital Hamburg-Eppendorf — Hamburg, Germany
Seoul National University Bundang Hospital — Seongnam-si, South Korea
Samsung Medical Center — Seoul, South Korea
The Catholic University of Korea St. Vincent's Hospital — Suwon, South Korea
Vall d'Hebron Institute of Oncology — Barcelona, Spain
University Hospital Foundation Jimenez Diaz — Madrid, Spain
University Hospital HM Sanchinarro — Madrid, Spain
Hospital Clinic Universitario Biomedical Research institute INCLIVA — Valencia, Spain
Institute of Cancer Research - Royal Marsden — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.